<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5355">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01143766</url>
  </required_header>
  <id_info>
    <org_study_id>0911-51</org_study_id>
    <nct_id>NCT01143766</nct_id>
  </id_info>
  <brief_title>Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)</brief_title>
  <official_title>Premedication With Single Dose Gabapentin to Improve Patient Tolerance in ERCP: A Double-Blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard approach to sedation in endoscopic retrograde cholangiopancreatography (ERCP)
      involves the use of benzodiazepines and opiates to achieve a moderate depth of sedation.
      There is data to suggest supplementing this regimen with gabapentin may lead to reduced
      pain, higher patient satisfaction and lower opiate requirements. The investigators are
      conducting a clinical trial to study this hypothesis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Dosing Requirements</measure>
    <time_frame>At time of discharge post-procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the effect of a single 900mg dose of gabapentin pre- ERCP on intra and post procedure narcotic/sedative requirements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>At time of discharge post-procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Measure sedation-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>At time of discharge post-procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the effect of a single 900mg dose of gabapentin pre-ERCP on pre and post procedure pain, anxiety and nausea as reported on visual analog scales.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Conscious Sedation</condition>
  <arm_group>
    <arm_group_label>Standard sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gapabentin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure</description>
    <arm_group_label>Gapabentin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard sedation regimen</intervention_name>
    <description>Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.</description>
    <arm_group_label>Standard sedation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients &gt;18 years of age referred to IUMC for first-time ERCP
             procedure.

        Exclusion Criteria:

          1. Pregnant women

          2. age &lt;18 years

          3. Incarcerated individuals

          4. Patients currently taking or having taken gabapentin or pregabalin within the last 3
             months

          5. Patients unable to give informed consent

          6. Patients not able to fill out visual analog scales for pain, nausea and anxiety or
             unable to fill out survey regarding procedural satisfaction.

          7. High risk patients for anesthesia: home oxygen, class III or IV heart failure, sleep
             apnea (on CPAP/BiPAP at home), or ASA class &gt; 3.

          8. Patients undergoing general anesthesia for their ERCP procedure

          9. Patients receiving propofol sedation for their ERCP procedure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory A Cote, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Indiana University Purdue University Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 6, 2012</lastchanged_date>
  <firstreceived_date>June 11, 2010</firstreceived_date>
  <firstreceived_results_date>September 20, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Gregory A. Cote</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Medicine</investigator_title>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>Gabapentin</keyword>
  <keyword>ERCP</keyword>
  <keyword>Endoscopy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard Sedation</title>
          <description>Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.</description>
        </group>
        <group group_id="P2">
          <title>Gapabentin</title>
          <description>Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Sedation</title>
          <description>Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.</description>
        </group>
        <group group_id="B2">
          <title>Gapabentin</title>
          <description>Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="56"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="48"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="49.1" spread="16.6"/>
                <measurement group_id="B2" value="48.1" spread="12.8"/>
                <measurement group_id="B3" value="48.6" spread="14.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="34"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="56"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dosing Requirements</title>
        <description>Assess the effect of a single 900mg dose of gabapentin pre- ERCP on intra and post procedure narcotic/sedative requirements.</description>
        <time_frame>At time of discharge post-procedure</time_frame>
        <safety_issue>No</safety_issue>
        <population>TOTAL DOSE OF MEPERIDINE</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Sedation</title>
            <description>Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Gapabentin</title>
            <description>Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="31"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Dosing Requirements</title>
            <description>Assess the effect of a single 900mg dose of gabapentin pre- ERCP on intra and post procedure narcotic/sedative requirements.</description>
            <units>TOTAL DOSE OF MEPERIDINE, mg</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="100" lower_limit="88" upper_limit="125"/>
                  <measurement group_id="O2" value="100" lower_limit="100" upper_limit="150"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <description>Measure sedation-related adverse events</description>
        <time_frame>At time of discharge post-procedure</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy</title>
        <description>Assess the effect of a single 900mg dose of gabapentin pre-ERCP on pre and post procedure pain, anxiety and nausea as reported on visual analog scales.</description>
        <time_frame>At time of discharge post-procedure</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Sedation</title>
          <description>Patients will receive combination opiate and benzodiazepine for sedation, the current standard of care.</description>
        </group>
        <group group_id="E2">
          <title>Gapabentin</title>
          <description>Patients will receive gabapentin 900mg PO x 1 dose, one hour prior to the procedure. At the time of ERCP, patients will be sedated in a standard fashion.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited sample size due to challenges with recruitment and transition to propofol-based anesthesia for sedation in ERCP. Study terminated at 50% enrollment for this reason.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gregory A. Cote</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-944-2740</phone>
      <email>gcote@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
